Avid Bioservices Inc (CDMO)

[cjgaddy]

PPHM's Jeff Hutchins(VP/PreClinRes) speaking 3-8-16 at CHI’s Inaugural-Cancer-Immunotherapy Conf. (SanFran). Dr. Hutchins is chairing the “Emerging Strategies For Checkpoint Inhibitor Combination Immunotherapy” track…

Mar6-11 2016: “CHI’s 23rd Molecular Med. TRI-CON 2016”, SanFran http://www.triconference.com
"Attracting over 3,300 drug discovery & dev. professionals from over 40 countries in 2015, the Tri-Conference has grown into a diverse event, focusing on Molecular Medicine, specifically on Discovery, Genomics, Diagnostics, and Info. Technology."
CHI = Cambridge Healthtech Institute http://www.healthtech.com
INAUGURAL CANCER IMMUNOTHERAPY CONF. - Emerging Biology, Targets and Strategies
Mar7–9 2016 (part of the 23rd Intl. Molecular Medicine Tri-Conf.)
http://www.triconference.com/Cancer-Immunotherapy
Track: EMERGING STRATEGIES FOR CHECKPOINT INHIBITOR COMBINATION IMMUNOTHERAPY
Chairperson: Jeff T. Hutchins (PhD, VP/PreclinRes., Peregrine Pharm.)
3-8-16 2pm: Chairperson Jeff Hutchins' Remarks
3-8-16 3:55pm: “Combination Immunotherapies – Opening the Gate: Increasing Tumor Infiltrating Activated T-Cells to Optimize and Expand the Benefits of Immune Checkpoint Therapies” Jeff T. Hutchins (Peregrine)
OVERVIEW: PD-1 & CTLA-4-targeting drugs have significantly improved patient survival in both melanoma and NSCLC, although their efficacy has been limited to a minority of subjects. Phosphatidylserine (PS)-targeting antibodies have demonstrated the ability to override tumor immune suppression and reactivate immune responses when combined with immunotherapies, chemotherapies, radiation, and targeted treatments. Recent translational data demonstrate the potential of PS-targeting antibodies to mediate immune activation and improved anti-tumor responses in low PD-L1 tumor samples.